dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lozano, Maria L. |
dc.contributor.author | Segú-Vergés, Cristina |
dc.contributor.author | Coma, Mireia |
dc.contributor.author | González-Porras, José R. |
dc.contributor.author | Gutiérrez, Laura |
dc.contributor.author | Valcarcel Ferreiras, David |
dc.contributor.author | Álvarez Román, María Teresa |
dc.date.accessioned | 2022-02-22T07:38:17Z |
dc.date.available | 2022-02-22T07:38:17Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Lozano ML, Segú-Vergés C, Coma M, Álvarez-Roman MT, González-Porras JR, Gutiérrez L, et al. Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. Int J Mol Sci. 2021 Jul;22(13):6907. |
dc.identifier.issn | 1422-0067 |
dc.identifier.uri | https://hdl.handle.net/11351/7053 |
dc.description | Intel·ligència artificial; Eltrombopag; Trombocitopènia immune primària |
dc.description.sponsorship | This research was funded and promoted by Novartis, which contributed to setting up fundamental questions relevant for the study and reviewing the manuscript. However, the company did not have a role on study design, data collection, analysis, or interpretation. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | International Journal of Molecular Sciences;22(13) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Trombocitopènia - Tractament |
dc.subject | Trombopoetina - Receptors |
dc.subject.mesh | Purpura, Thrombocytopenic, Idiopathic |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Receptors, Thrombopoietin |
dc.subject.mesh | /antagonists & inhibitors |
dc.title | Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/ijms22136907 |
dc.subject.decs | púrpura trombocitopénica idiopática |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | receptores de trombopoyetina |
dc.subject.decs | /antagonistas & inhibidores |
dc.relation.publishversion | https://doi.org/10.3390/ijms22136907 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lozano ML] Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CB15/00055-CIBERER, 30007 Murcia, Spain. [Segú-Vergés C, Coma M] Anaxomics Biotech S.L., 08007 Barcelona, Spain. [Álvarez-Roman MT] Unidad de Trombosis y Hemostasia, Servicio de Hematología, Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain. [González-Porras JR] Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain. [Gutiérrez L] Grupo de Investigación en Plaquetas, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Departamento de Medicina, Universidad de Oviedo, 33071 Oviedo, Spain. [Valcárcel D] Vall d’Hebron Insitute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34199099 |
dc.identifier.wos | 000670936400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |